CompletedPhase 2NCT03026504

Baricitinib in Relapsing Giant Cell Arteritis

Studying Giant cell arteritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Matthew J Koster
Principal Investigator
Kenneth Warrington, MD
Mayo Clinic
Intervention
Baricitinib(drug)
Enrollment
15 target
Eligibility
50 years · All sexes
Timeline
20172021

Study locations (1)

Collaborators

Eli Lilly and Company

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03026504 on ClinicalTrials.gov

Other trials for Giant cell arteritis

Additional recruiting or active studies for the same condition.

See all trials for Giant cell arteritis

← Back to all trials